UCB and Synosia sign neurology agreement

Switzerland-based Synosia Therapeutics has granted UCB exclusive, worldwide rights to its development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications.

Switzerland-based Synosia Therapeutics has granted UCB exclusive, worldwide rights to its development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications. Both are in Phase II clinical development for the treatment of Parkinson’s disease. UCB takes responsibility for Phase III clinical development and commercialisation.

Under the agreement, UCB, based in Brussels, Belgium, will make an equity investment of US$20m in Synosia.

The Basel-based company will also receive an undisclosed upfront payment and is eligible to receive regulatory and commercial milestone payments of up to US$725m across both compounds. In addition, two representatives of UCB will join Synosia’s board of directors.

The agreement also allows for additional compounds from either company’s pipeline to be brought into the collaboration on terms to be negotiated.

‘With access to these two potentially important new treatments for people living with movemen